

SUSTAINABILITY ACCOUNTING STANDARDS BOARD (SASB) INDEX 2024

Fresenius Group compiles and discloses data based on the metrics of the Sustainability Accounting Standards Board (SASB) in its Index 2024. Going forward, we continuously strive to improve our disclosure of quantitative metrics and further enhance our SASB reporting. With this process, we are acknowledging the importance of the SASB standard among our investors.

Our disclosures are based on the Sustainable Industry Classification System (SICS) industries within the health industry sector, with a focus on those sectors that best reflect our different business fields: **Biotechnology & Pharmaceuticals (BP), Health Care Delivery (DY), Health Care Distributors (DI), and Medical Equipment & Supplies (MS)**. Due to the diversified business model of Fresenius SE & Co. KGaA and its subsidiaries, only those indicators of the identified industry standards which are relevant for our operations are included in the index provided.

The majority of references within this index refer to the Fresenius 2024 Group Annual Report (see: https://report.fresenius.com/2024/annual-report/_assets/downloads/entire-fresenius-ar24.pdf) and the Fresenius 2024 Sustainability Statement (see pages 148 ff. of the Group Annual Report 2024).

Unless otherwise stated, all reported data are as of December 31, 2024.

Topic	Code	Accounting metric	Comment and link
Biotechnology & Pharmaceuticals			
Safety of Clinical Trial Participants	HC-BP-210a.1	Discussion, by region, of management process for ensuring quality and patient safety during clinical trials	<p>Fresenius Group reports on the management approach with regard to clinical trials and clinical study management as well as on its organization and relevant guidelines or policies. Information provided focuses on clinical studies in pharmaceutical approval processes in our healthcare products market segment and innovative treatment concepts in the healthcare services market segment. It is ensured that scientific, ethical and legal requirements are met. Only studies with an existing ethical vote and in compliance with all patients' rights are carried out. Detailed information is provided to a patient who decides to participate in a study by specially trained and dedicated staff. Patients are free to decide whether or not to participate.</p> <p>Fresenius Group Sustainability Report 2024: Social information > Innovation > Our approach > Treatment concepts, health services research, and clinical studies (pg. 276 f.)</p> <p>Caring for Human Rights: https://www.fresenius.com/human-rights</p>
	HC-BP-210a.2	Number of inspections related to clinical trial management and pharmacovigilance that resulted in: (1) entity voluntary remediation or (2) regulatory or administrative actions taken against the entity	<p>Fresenius Group reports on the management approach with regard to clinical trials and clinical study management as well as on its organization and relevant guidelines or policies. Information is provided for all business segments with a focus on clinical study management in our hospitals. It is ensured that scientific, ethical and legal requirements are met. Only studies with an existing ethical vote and in compliance with all patients' rights are carried out. Detailed information is provided to a patient who decides to participate in a study by specially trained and dedicated staff. Patients are free to decide whether or not to participate. Inspections conducted by external bodies are not published separately. At Fresenius Kabi, the total number of inspections in the reporting year is provided.</p> <p>Fresenius Group Sustainability Report 2024: Social information > S4 Consumers and end-users > Health and safety > Metrics > Quality standards at Fresenius Kabi > Audits and inspections: Table "Audits and inspections" (pg. 267)</p>
	HC-BP-210a.3	Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	All relevant legal proceedings and related financial affects are disclosed in our Fresenius Group Annual Report 2024 - Note 33: Commitments and contingencies (pg. 366 f.)
Access to Medicines	HC-BP-240a.1	Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index	<p>Fresenius Group Sustainability Report 2024: Social information > S4 Consumers and end-users</p> <ul style="list-style-type: none"> > Access to products and services (pg. 269) > Access to products and services > Our approach (pg. 270) > Access to products and services > Our approach > Access to healthcare and medicine > Patient support in crisis and emergency situations (pg. 271 f.) <p>Cooperation and social activities 2024: https://www.fresenius.com/our-responsibility</p>

	HC-BP-240a.2	List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	Fresenius Kabi has one entity mentioned as API manufacturing site for two listed products on the WHO List of Prequalified Medicinal Products as of the reporting year 2024. For more information, click here: https://extranet.who.int/prequal/medicines/ha479 https://extranet.who.int/prequal/medicines/ha480 https://extranet.who.int/prequal/vaccines/comirnaty
Drug Safety	HC-BP-250a.1	Products listed in public medical product safety or adverse event alert databases	Fresenius Group Sustainability Report 2024: Social Information > S4 Consumers and end-users > Health and safety > Our approach > Quality Management at Fresenius Kabi > Early-warning systems in product risk management (pg. 259) Please refer to MedWatch: The FDA Safety Information and Adverse Event Reporting Program: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program
	HC-BP-250a.2/ HC-MS-250a.3	Number of fatalities associated with products	Fresenius Group Sustainability Report 2024: Social Information > S4 Consumers and end-users > Health and safety > Our approach > Quality Management at Fresenius Kabi > Early-warning systems in product risk management (pg. 259)
	HC-BP-250a.3/ HC-MS-250a.1	(1) Number of recalls issued, (2) total units recalled	Fresenius Group does not report on the numbers of recalls or total units recalled. It is our aim to act fast and proactively concerning recall execution in order to minimize potential risks for patients. The recalls are discussed and agreed on beforehand in cooperation with the respective authority. For information on our approach towards recalls, see: Fresenius Group Sustainability Report 2024: Social information > S4 Consumers and end-users > Health and safety > Our approach > Quality Management at Fresenius Kabi > Early-warning systems in product risk management (pg. 259) Example: Fresenius Kabi – Pharmaceutical Products https://www.fresenius-kabi.com/us/pharmaceutical-products https://www.fresenius-kabi.com/us/pharmaceutical-product-updates See: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts?search_api_fulltext=Fresenius&field_regulated_product_field=All
	HC-BP-250a.5/ HC-MS-250a.4	Number of enforcement actions taken in response to violations of good manufacturing practices (GMP) or equivalent standards, by type	We report on inspections and enforcement actions taken, if material for the operating business, in our quarterly and annual reports. Fresenius Group Annual Report 2024: Key characteristics of the Fresenius risk management system and internal control system (pg. 137 f.) Fresenius Group Sustainability Report 2024: Social information > S4 Consumers and end-users > Health and safety > Metrics > Quality standards at Fresenius Kabi > Audits and inspections: Table "Audits and inspections" (pg 267)
Counterfeit Drugs	HC-BP-260a.1/ HC-DI-260a.1	Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting	Fresenius Group Sustainability Report 2024: Social information > S4 Consumers and end-users > Health and safety > Our approach > Quality Management at Fresenius Kabi > Labeling and product information (pg. 259) Social information > Digital transformation > Our approach > Digitalization strategies > Digital processes and applications (pg. 282) Fresenius Kabi Drug Supply Chain Security Act (DSCSA): https://www.fresenius-kabi.com/us/drug-supply-chain-security-act-dscsa

Ethical Marketing	HC-BP-270a.1/ HC-MS-270a.1	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	All relevant legal proceedings and related financial affects are disclosed in our Fresenius 2024 Group Annual Report - Note 33: Commitments and contingencies (pg. 366 f.)
	HC-BP-270a.2/ HC-MS-270a.2	Description of code of ethics governing promotion of off-label use of products	<p>Fresenius Kabi: https://www.fresenius-kabi.com/content/dam/fresenius-kabi/global/documents/guidelines/Fresenius-Kabi-Code-of-Conduct-2022.pdf.coredownload.inline.pdf</p> <p>Fresenius Group Sustainability Report 2024: Social information > S4 Consumers and end-users > Health and safety of patients > Our approach > Quality Management at Fresenius Kabi > Labeling and product information (pg. 259)</p>
Employee Recruitment, Development & Retention	HC-BP-330a.1	Discussion of talent recruitment and retention efforts for scientists and research and development staff	<p>We place special importance on those employees, who support our ambitions on innovative treatment concepts and product innovations. For overarching measures, please see:</p> <p>Fresenius Group Sustainability Report 2024: Innovation (pg. 273) Social information > S1 Own workforce > Our approach > Policies related to working conditions > Recruitment (pg. 213) > Employee development (pg. 214) > Employee retention (pg. 215)</p>
	HC-BP-330a.2	(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) midlevel managers, (c) professionals, and (d) all others	<p>Fresenius discloses the voluntary turnover, but not as a break-down for management levels. We aim to improve the reporting scope on recruitment data going forward and assess internally to add further KPIs for this aspect.</p> <p>Fresenius Group Sustainability Report 2024: Social information > S1 Own workforce > Our approach > Policies related to working conditions > Employee retention (pg. 215) > Metrics > characteristics of the employees > Table: "Employee termination" (pg. 231)</p>
Business Ethics	HC-BP-510a.1/ HC-DI-510a.2/ HC-MS-510a.1	Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery	All relevant legal proceedings and related financial affects are disclosed in our Fresenius 2024 Group Annual Report - Note 33: Commitments and contingencies (pg. 366 f.)
	HC-BP-510a.2/ HC-MS-510a.2	Description of code of ethics governing interactions with health care professionals	<p>Fresenius Group Sustainability Report 2024: Governance information > G1 Business conduct > Our approach > Business conduct policies and corporate culture (pg. 286) Social information > S4 Consumers and end-users > Health and safety > Our approach > Group-wide quality management for patient and product safety > Compliance with international requirements and internal guidelines (pg. 256) > Quality Management at Fresenius Kabi > Labeling and product information (pg. 259)</p> <p>Fresenius Group Compliance: https://www.fresenius.com/compliance</p>
Activity metrics	HC-BP-000.A	Number of patients treated	Fresenius Group Sustainability Report 2024: Social information > S4 Consumers and end-users > Access to healthcare and medicine > Metrics > Number of patients Fresenius Helios > Table: "Number of patients" (pg. 273)
	HC-BP-000.B	Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3)	Please refer to our Capital Markets Day 2023: https://www.fresenius.com/sites/default/files/2023-05/Fresenius_CMD_2023_Presentation_0.pdf

Health Care Delivery			
Energy Management	HC-DY-130a.1	(1) Total energy consumed, (2) percentage grid electricity, (3) percentage renewable	<p>Fresenius Group Sustainability Report 2024: Environmental Information > E1 Climate change > Metrics > Energy consumption and energy mix > Table Energy consumption and mix (pg. 194)</p> <p>(1) Fresenius Group reports the total energy consumption in MWh. Converted into GJ, Fresenius Group consumed 11,682,201.78 GJ (3.245.056,05 MWh) in 2024. (2) 36.0% (3) 26% of total energy consumption (23% electricity (renewable), 3% renewable fuels)</p>
Waste Management	HC-DY-150a.2	Total amount of: (1) hazardous and (2) non-hazardous pharmaceutical waste, percentage (a) incinerated, (b) recycled or treated and (c) landfilled	<p>Waste treatment types according to CSRD are reported in our Fresenius Group Sustainability Report 2024: Environmental information > ESRS E5 Resource use and circular economy > Metrics > Resource outflows > Table: "Waste generated: recovery operations and treatment types" (pg. 209)</p> <p>Additional information on waste in relation to hospital beds (Fresenius Helios) is provided in our ESG KPI Overview: https://www.fresenius.com/our-responsibility</p>
Patient Privacy & Electronic Health Records	HC-DY-230a.2	Description of policies and practices to secure customers' personal health data records and other personal data	<p>Fresenius Group Sustainability Report 2024: Social Information > S4 Consumers and end-users > Information-related impacts for consumers and/or end-users > Privacy > Our approach (pg. 250) > Engaging with patients (pg. 253)</p>
	HC-DY-230a.3	(1) Number of data breaches, (2) percentage involving (a) personal data only and (b) personal health data, (3) number of customers affected in each category, (a) personal data only and (b) personal health data	<p>Fresenius Group Sustainability Report 2024: > Governance Information > G1 Business conduct > Metrics > Compliance reports (pg. 296) > Social Information > S4 Consumers and end-users > Information-related impacts for consumers and/or end-users: Privacy > Privacy > Engaging with patients > Reporting systems (pg. 253 f.)</p>
	HC-DY-230a.4	Total amount of monetary losses as a result of legal proceedings associated with data security and privacy	<p>All relevant legal proceedings and related financial affects are disclosed in our Fresenius 2024 Group Annual Report - Note 33: Commitments and contingencies (pg. 366 f.)</p>
Quality of Care & Patient Satisfaction	HC-DY-250a.2	Number of serious reportable events	<p>Fresenius Group reports on serious reportable events with regard to treatments in hospitals and healthcare facilities (Fresenius Helios). We provide information both on serious events as well as critical incidents in our Fresenius Group Sustainability Report 2024.</p> <p>Fresenius Group Sustainability Report 2024: Soical Information > S4 Consumers and end-users > Health and safety > Metrics > Fresenius Helios > Patient-relevant reports: Avoidable incidents (pg. 269)</p>
	HC-DY-250a.3	Hospital-acquired condition rates per hospital	<p>The Hospital-Acquired Condition rate is not calculated for hospitals and healthcare facilities of Fresenius Helios. However, we report on indicators in our hospitals and healthcare facilities which are comparable to those of the HAC Score, please refer to: https://www.helios-gesundheit.de/qualitaet/erreger/</p> <p>Fresenius Group Sustainability Report 2024: Social information > S4 Consumers and end-users > Health and safety > Our approach > Group-wide quality management for patient and product safety (pg. 255 f.)</p>

Management of Controlled Substances	HC-DY-260a.1	Description of policies and practices to manage the number of prescriptions issued for controlled substances	<p>In the area of hygiene management, Helios focuses in Germany and Spain on the following aspects, among others: close monitoring of infections and pathogens, regular hygiene training for hospital staff (e.g. on correct hand disinfection) and monitoring antibiotic consumption. The implementation of and compliance with hospital hygiene measures in our German and Spanish clinics is accompanied and monitored by specially trained staff – e.g. specialist hygiene nurses, hospital hygienists, and hygiene officers.</p> <p>Fresenius Group Sustainability Report 2024: Social information > S4 Consumers and end-users > Health and safety of patients > Our approach > Treatment quality at Fresenius Helios > Hygiene management in our hospitals (pg. 261)</p> <p>List of antibiotics and amount per antibiotic used in treatments overall and per clinic in Germany of Fresenius Helios: https://www.helios-gesundheit.de/qualitaet/antibiotika/ (available in German language only)</p>
Workforce Health & Safety	HC-DY-320a.1	Total recordable incident rate (TRIR) for (a) direct employees and (b) contract employees	<p>We disclose the lost time injury frequency rate (LTIFR) for Fresenius Kabi and Fresenius Helios in Spain. Fresenius Helios Germany is currently implementing the LTIFR.</p> <p>Fresenius Group Sustainability Report 2024: Social information > S1 Own workforce > Metrics > Health and Safety Metrics (pg. 236)</p>
Employee Recruitment, Development & Retention	HC-DY-330a.1	(1) Voluntary and (2) involuntary turnover rate for: (a) physicians, (b) non-physician health care practitioners, and (c) all other employees	<p>We do not provide a split for physicians, non-physician healthcare practitioners but only for all employees in a business segment. However, the majority of employees are nurses and medical staff.</p> <p>Fresenius Group Sustainability Report 2024: Social information > S1 Own workforce > Our approach > Policies related to working conditions > Employee retention (pg. 215) > Metrics > characteristics of the employees > Table: "Employee termination" (pg. 231)</p>
	HC-DY-330a.2	Description of talent recruitment and retention efforts for health care practitioners	<p>Fresenius Group Sustainability Report 2024: Social information > S1 Own workforce > Our approach > Policies related to working conditions > Employee development (pg. 214) > Employee retention (pg. 215)</p>
Climate Change Impacts on Human Health & Infrastructure	HC-DY-450a.1	Description of policies and practices to address: (1) the physical risks because of an increased frequency and intensity of extreme weather events, (2) changes in the morbidity and mortality rates of illnesses and diseases associated with climate change and (3) emergency preparedness and response	<p>Fresenius Group is currently assessing the impacts of climate change on our operating business. In the future, we will assess the impact of Scope 3 emissions to include them in our targets as well. We will provide updates on these assessments in our sustainability reporting going forward.</p> <p>Fresenius Group Sustainability Report 2024: General information > ESRS 2 General disclosures > Strategy and management > The business model and our value chain > Our sustainability goals and programs (pg. 158) > Impact, risk an doportunity management > Climate-related scenario analysis (pg. 166 f.) > Impact, risk an doportunity management > Resilience analysis (pg. 167 ff.)</p> <p>Environmental information > Disclosures pursuant to Article 8 of Regulation (EU) 2020/852 (Taxonomy Regulation) (pg. 177 ff.) > E1 Climate Change (pg. 186 ff.)</p> <p>Social information > S4 Consumers and end-users > Access to healthcare and medicine > Our approach > Access to healthcare and medicine > Patient support in crisis and emergency situations (pg. 271 f.)</p>
Fraud & Unnecessary Procedures	HC-DY-510a.1	Total amount of monetary losses as a result of legal proceedings associated with medical fraud	<p>All relevant legal proceedings and related financial affects are disclosed in our Fresenius 2024 Group Annual Report - Note 33: Commitments and contingencies (pg. 366 f.)</p>
Activity metrics	HC-DY-000.A	Number of (1) facilities and (2) beds, by type	<p>Fresenius Group Annual Report 2024: Group Management Report > Economic Report > The hospital market (pg. 109 f.)</p> <p>ESG KPI Overview: https://www.fresenius.com/our-responsibility</p>

	HC-DY-000.B	Number of (1) inpatient admissions and (2) outpatient visits	Fresenius Group Sustainability Report 2024: Social information > S4 Consumers and end-users > Access to healthcare and medicine > Metrics > Number of patients Fresenius Helios > Table: "Number of patients" (pg. 273)
Health Care Distributors			
Product Safety	HC-DI-250a.1	Total amount of monetary losses as a result of legal proceedings associated with product safety	All relevant legal proceedings and related financial affects are disclosed in our Fresenius 2024 Group Annual Report - Note 33: Commitments and contingencies (pg. 366 f.)
	HC-DI-250a.2	Description of efforts to minimize health and safety risks of products sold associated with toxicity/chemical safety, high abuse potential, or delivery	Fresenius Group Annual Report 2024: Opportunities and risk report > Significant characteristics of the Fresenius risk management system and entire internal control system (pg. 137 f.) Fresenius Group Sustainability Report 2024: Social information > S4 Consumers and end-users > Health and safety > Our approach > Group-wide quality management for patient and product safety (pg. 255 f.)
Counterfeit Drugs	HC-DI-260a.1/ HC-BP-260a.1	Description of methods and technologies used to maintain traceability of products throughout the distribution chain and prevent counterfeiting	see HC-BP-260a.1
	HC-DI-260a.2	Discussion of due diligence process to qualify suppliers of drug products and medical equipment and devices	Suppliers related to product manufacturing are subject to qualification processes based on the relevance of the delivered material or service. In the healthcare products market segment, the supplier's qualification and their recertification is regularly audited. Fresenius Group Sustainability Report 2024: Social information > S4 Consumers and end-users > Health and safety > Our approach > Quality management at Fresenius Kabi (pg. 258 f.) Social information> S2 Workers in the value chain > Our approach (pg. 242 ff.) > Our actions > Risk analysis and measures (pg. 247 f.)
	HC-DI-260a.3	Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products	Fresenius Group Sustainability Report 2024: Social information > S4 Consumers and end-users > Health and safety of patients > Our approach > Quality Management at Fresenius Kabi > Early-warning systems in product risk management (pg. 259) Fresenius Kabi - Pharmaceutical Products: https://www.fresenius-kabi.com/us/pharmaceutical-products
Business Ethics	HC-DI-510a.1	Description of efforts to minimize conflicts of interest and unethical business practices	Fresenius Group Sustainability Report 2024: Governance information > G1 Business conduct > Our approach > Business conduct policies and corporate culture (pg. 286 ff.) Fresenius Group Annual Report 2024: Corporate Governance > Corporate Governance Declaration > Independence and conflicts of interest (pg. 30)
	HC-DI-510a.2	Total amount of monetary losses as a result of legal proceedings associated with bribery, corruption, or other unethical business practices	All relevant legal proceedings and related financial affects are disclosed in our Fresenius 2024 Group Annual Report - Note 33: Commitments and contingencies (pg. 366 f.)
Activity metrics	HC-DI-000.A	Number of pharmaceutical units sold by product category	We do not disclose the number of pharmaceutical units sold by product category, only sales by product segment. #FutureFresenius – REJUVENATE for next level performance: https://www.fresenius.com/sites/default/files/2025-02/FRE%20DE%20Q4%2024%20Web_0.pdf

	HC-DI-000.B	Number of medical devices sold by product category	We do not disclose the number of medical devices sold by product category, only sales by product segment. #FutureFresenius – REJUVENATE for next level performance: https://www.fresenius.com/sites/default/files/2025-02/FRE%20DE%20Q4%2024%20Web_0.pdf
Medical Equipment & Supplies			
Product Safety	HC-MS-250a.1	(1) Number of recalls issued, (2) total units recalled	see HC-BP-250a.3
	HC-MS-250a.2	Products listed in any public medical product safety or adverse event alert database	Please refer to the FDA Adverse Event Reporting: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program Fresenius Group Sustainability Report 2024: Social information > S4 Consumers and end-users > Health and safety of patients > Our approach > Quality Management at Fresenius Kabi > Early-warning systems in product risk management (pg. 259)
	HC-MS-250a.3	Number of fatalities associated with products	see HC-BP-250a.2
	HC-MS-250a.4	Number of enforcement actions taken in response to violations of good manufacturing practices (GMP) or equivalent standards, by type	In the reporting year, there were no actions taken that stand against our quality goals. Guidelines of Good Manufacturing Practice (GMP) and current Good Manufacturing Practice (cGMP) guidelines are taken into account, see: Fresenius Group Sustainability Report 2024: Social information > S4 Consumers and end-users > Health and safety > Our approach > Group-wide quality management for patient and product safety > Compliance with international requirements and internal guidelines (pg. 256 ff.) > Quality Management at Fresenius Kabi (pg. 258 ff.)
Ethical Marketing	HC-MS-270a.1	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	All relevant legal proceedings and related financial affects are disclosed in our Fresenius 2024 Group Annual Report - Note 33: Commitments and contingencies (pg. 366 f.)
	HC-MS-270a.2	Description of code of ethics governing promotion of off-label use of products	We provide information in the codes of ethics and conduct of our business segments governing promotion of off-label use of products, if applicable. Example: https://www.fresenius-kabi.com/content/dam/fresenius-kabi/global/documents/guidelines/Fresenius-Kabi-Code-of-Conduct-2022.pdf.coredownload.inline.pdf
Product Design & Lifecycle Management	HC-MS-410a.2	Total amount of products accepted for takeback and reused, recycled, or donated, broken down by: (1) devices and equipment and (2) supplies	In the health sector, the takeback, reuse and recycling of our products and materials is regulated on national level. Fresenius Group does not report on the total amount of products accepted for takeback and reused, recycled, or donated. We report on resource inflows and outflows: Fresenius Group Sustainability Report 2024: Environmental information > E5 Resource use and circular economy > Metrics (pg. 207 ff.)
Supply Chain Management	HC-MS-430a.1	Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in third-party audit programs for manufacturing and product quality	Fresenius Group aims to improve the reporting scope on supply chain going forward. Fresenius Group Sustainability Report 2024: Social Information > S2 Workers in the value chain (pg. 242 ff.)
	HC-MS-430a.2	Description of efforts to maintain traceability within the distribution chain	Fresenius Kabi - Drug supply chain security act: https://www.fresenius-kabi.com/us/drug-supply-chain-security-act-dscsa Fresenius Group Sustainability Report 2024: Social Information > S2 Workers in the value chain (pg. 242 ff.)

	HC-MS-430a.3	Description of the management of risks associated with the use of critical materials	<p>Before the EU Conflict Minerals Regulation came into force, Fresenius SE & Co. KGaA and its operating units already addressed this sensitive issue. We do not purchase conflict minerals directly. However, it cannot be completely ruled out that they have been processed in components and semifinished products that we purchase and further process or use in our products. In this case, our purchasing guidelines apply, as do the relevant Group and business segment codes of conduct for dealing with suppliers and other business partners.</p> <p>Fresenius Group Sustainability Report 2024: Social Information > S2 Workers in the value chain (pg. 242 ff.)</p>
Business Ethics	HC-MS-510a.1/ HC-BP-510a.1/ HC-DI-510a.2	Total amount of monetary losses as a result of legal proceedings associated with bribery or corruption	<p>Fresenius Group reports on impacts from legal proceedings in the 2024 Group Annual Report, see Note 33: Commitments and Contingencies (pg. 366 f.)</p>
	HC-MS-510a.2	Description of code of ethics governing interactions with health care professionals	<p>Fresenius Group Sustainability Report 2024: General information > ESRS 2 General disclosures > Strategy and management > Stakeholder and partnerships (pg. 159 ff.) Governance information > G1 Business conduct > Our approach > Business conduct policies and corporate culture (pg. 286 ff.)</p> <p>Fresenius Code of Conduct: https://www.fresenius.com/sites/default/files/2022-01/FRS_Code_of_Conduct_ext.pdf</p>